Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 17/20 | 0.72 |
| ▸ | DDR2 | Q16832 | 16/20 | 0.72 |
| ▸ | KIT | P10721 | 9/20 | 0.72 |
| ▸ | ABL1 | P00519 | 6/20 | 0.67 |
| ▸ | BCR | P11274 | 2/20 | 0.67 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.57 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.57 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.57 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24071021 | 0.91 | DDR1 (0.65) | DDR1DDR2KITABL1BCR | |
| SCHEMBL30211938 | 0.91 | DDR1 (0.69) | DDR1DDR2KITABL1BCR | |
| SCHEMBL25339556 | 0.91 | DDR1 (0.69) | DDR1DDR2KITABL1BCR | |
| SCHEMBL24070474 | 0.84 | DDR2 (0.66) | DDR1DDR2KITABL1BCR | |
| SCHEMBL3430553 | 0.84 | DDR1 (1.00) | DDR1DDR2KITABL1BCR | |
| SCHEMBL30340317 | 0.82 | DDR2 (0.56) | DDR1DDR2KITABL1BCR | |
| SCHEMBL24070472 | 0.82 | DDR2 (0.56) | DDR1DDR2KITABL1BCR | |
| SCHEMBL30211923 | 0.81 | ABL1 (0.59) | KITABL1BCR | |
| SCHEMBL24070155 | 0.81 | ABL1 (0.59) | KITABL1BCR | |
| SCHEMBL27974634 | 0.81 | DDR1 (1.00) | DDR1DDR2KITABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697485-B | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2025-03-14 | — | — | CN | claimed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | claimed |
| EP-4157447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-04-05 | — | — | EP | claimed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115697485-B | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| EP-4157447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-04-05 | — | — | EP | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021239643-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | DDR1 2/4885DDR2 1/4885KIT 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.